Latest Conference Articles

Eliya Shachar, UCLA Health, says toxicity risk is not independently tied to age or demographics, reinforcing consistent monitoring and individualized care for all patients.

Nurses can catch early IO toxicities through routine symptom checks and support long-term care, as effects may persist after treatment ends.

Zongertinib elicited responses in patients with advanced HER2-mutant NSCLC, showing intracranial efficacy in those with active brain metastases, per phase 1b Beamion LUNG-1 data.

Adagrasib shows efficacy in elderly patients with KRAS G12C-mutant NSCLC and an ECOG PS of 0-1, while those with a PS of 2 see limited survival benefit but QOL improvements.

Calderasib, a potent KRAS G12C inhibitor, demonstrated improved outcomes in patients with metastatic NSCLC, especially when combined with pembrolizumab.

Explore phase 1 data for setidegrasib, a novel KRAS G12D-targeted protein degrader showing antitumor activity and manageable infusion-related reactions in patients with advanced NSCLC.

Research presented at the APOS Conference demonstrated negative beliefs in parents and caregivers of pediatric patients with cancer.

Amber Altidor, NP, shares how oncology nurses can use teach-back methods and learning style assessments to improve patient education on medication toxicities.

Data presented at the annual APOS Conference revealed training and workflow issues in providing developmentally appropriate cancer care to AYA patients.

Radiation-induced heart damage in breast cancer is a growing clinical concern, yet biomarkers and preventive therapies remain lacking.

A multidisciplinary approach to care is key when addressing sexual health concerns among breast cancer survivors.

Mark S. Lin, MSN, FNP-BC, highlighted nursing considerations for breast reconstruction surgery in breast cancer.

Lillian Rodich, PA-C, MPH, stressed that nurses can take advantage of accessible and local integrative medicine resources to treat patients with cancer.

Don S. Dizon, MD, FACP, FASCO, shared insights on what pregnancy looks like with a breast cancer diagnosis and what those considering pregnancy should know.

Findings from real-world community clinics show favorable efficacy of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer.

Patricia Jakel, MN, RN, AOCN, shares how personal and professional experience impact her view on testing even beyond what is recommended.

What should oncology nurses and advanced practice providers understand about GLP-1 RAs in the care of patients with breast cancer?

Data show that sentinel lymph node biopsy is becoming less routine for older women with breast early stage HR-positive, HER2-negative breast cancer.

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment.

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04.

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger age groups with mccRCC.

Abiraterone/prednisone plus olaparib improves survival outcomes vs monotherapy or sequential use in BRCA1/2- or ATM-altered mCRPC.

Explore safety and efficacy findings from KEYNOTE-B15/EV-304, LITESPARK-011, and more from the ASCO Genitourinary Cancers Symposium.

An early but temporary decline in QOL followed by later cognitive effects and pain was seen in patients with RCC receiving adjuvant durvalumab/tremelimumab.

Adding 177Lu-PSMA-617 to ADT and an ARPI maintained health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

With the addition of pembrolizumab to standard androgen deprivation therapy and radiation, immune-related adverse events are more likely.

Phase 3 LITESPARK-011 trial results demonstrated PFS and ORR benefits with belzutifan plus lenvatinib vs cabozantinib in advanced ccRCC after ICI therapy.

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases.